A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults taking Opioid Therapy for Persistent Non-Cancer Pain
收藏NIAID Data Ecosystem2026-03-06 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2517462
下载链接
链接失效反馈官方服务：
资源简介：
Primary objectives: To compare alvimopan with placebo for efficacy in the treatment of OBD
Primary endpoints: Proportion of subjects responding on spontaneous BM frequency
创建时间：
2005-08-15
